Poor response to neoadjuvant chemotherapy in metaplastic breast carcinoma.

Wong, Willard, Brogi, Edi, Reis-Filho, Jorge S, Plitas, George, Robson, Mark, Norton, Larry, Morrow, Monica, Wen, Hannah Y (July 2021) Poor response to neoadjuvant chemotherapy in metaplastic breast carcinoma. npj Breast Cancer, 7 (1). p. 96. ISSN 2374-4677

[img] PDF
2021.Wong.metaplastic_breast_carcinoma.pdf
Available under License Creative Commons Attribution.

Download (1MB)
URL: https://www.ncbi.nlm.nih.gov/pubmed/34294707
DOI: 10.1038/s41523-021-00302-z

Abstract

Metaplastic breast carcinoma (MpBC) is a rare special histologic subtype of breast carcinoma characterized by the presence of squamous and/or mesenchymal differentiation. Most MpBCs are of triple-negative phenotype and neoadjuvant chemotherapy (NAC) is frequently utilized in patients with MpBC. The aim of this study was to evaluate response to NAC in a retrospective cohort of MpBCs. We identified 44 patients with MpBC treated with NAC at our center between 2002 and 2018. Median age was 48 years, 86% were clinical stage II-III, and 36% were clinically node-positive. Most (80%) MpBCs were triple-negative or low (1-10%) hormonal receptor positive and HER2 negative on pre-NAC biopsy. While on NAC, 49% showed no clinical response or clinico-radiological progression. Matrix-producing subtype was associated with clinico-radiological response (p = 0.0036). Post NAC, two patients initially ineligible for breast-conserving surgery (BCS) were downstaged to be eligible for BCS, whereas three patients potentially eligible for BCS before treatment became ineligible due to disease progression. Only one (2%) patient had a pathologic complete response (pCR). Among the 16 patients presenting with biopsy-proven clinical node-positive disease, 3 (19%) had nodal pCR. Axillary lymph node dissection was avoided in 3 (19%) patients who had successful axillary downstaging. Residual cancer burden (RCB) was assessed in 22 patients and was significantly associated with disease-free survival and overall survival. We observed a poor response or even disease progression on NAC among patients with MpBC, suggesting that NAC should be reserved for patients with inoperable MpBC.

Item Type: Paper
Subjects: diseases & disorders > cancer > cancer types > breast cancer
diseases & disorders > cancer > drugs and therapies > chemotherapy
diseases & disorders > cancer > drugs and therapies > patient outcomes
CSHL Authors:
Communities: CSHL labs > Wigler lab
SWORD Depositor: CSHL Elements
Depositing User: CSHL Elements
Date: 22 July 2021
Date Deposited: 09 Aug 2021 13:16
Last Modified: 09 Aug 2021 13:16
PMCID: PMC8298632
URI: https://repository.cshl.edu/id/eprint/40312

Actions (login required)

Administrator's edit/view item Administrator's edit/view item
CSHL HomeAbout CSHLResearchEducationNews & FeaturesCampus & Public EventsCareersGiving